 |
Novel breast cancer subtypes with integrative genomic and transcriptome analysis. omega replica
|
|
|
|
108-110 |
|
|
Cancer single pathways inhibitors: More resistance than durable success in the clinic |
|
|
|
111-117 |
|
|
Resistance to everolimus treatment of renal cancer, intratumor heterogeneity and new therapeutic approaches. |
|
|
|
118-120 |
|
|
Tumor diversity: Implementing NGS into clinic |
|
|
|
121-126 |
|
|
100 breast cancer genome sequencing: Heterogeneity-based diagnostic and therapeutic perspectives. |
|
|
|
127-130 |
|
|
Overcoming resistance to cetuximab or panitumumab in KRAS wild-type colorectal cancer. |
|
|
|
131-134 |
|
|
Triple-negative breast cancer: From microarrays basal-like subtype to NGS molecular classification and new drugs development. |
|
|
|
135-139 |
|
|
Robots and surgeons: Do patients benefit?
|
|
|
|
140-142 |
|
|
Neoadjuvant treatment and laparoscopic rectal cancer: Precision genomic medicine essential for improving patient's outcomes. |
|
|
|
143-145 |
|
|
Gastric cancer perspectives: Laparoscopic surgery and systems approach polypharmacology. |
|
|
|
146-148 |
|
|
Breast cancer advances in clinical cancer genome era: from conventional to integrative genome analysis. |
|
|
|
149-150 |
|
|
Vemurafenib plus cetuximab or gefitinib for BRAF(V600E) mutant colorectal cancer. |
|
|
|
151-153 |
|
|
Preoperative chemoradiotherapy for rectal cancer: Why revision and concerns are now shaped? |
|
|
|
154-156 |
10.2122/gbc.2012.0238 |
|
Total mesorectal excision for rectal cancer: Laparoscopic or robotic approach? |
|
|
|
157-159 |
10.2122/gbc.2012.0239 |
|
Dual inhibition of HER2 for a safe increase of efficacy in breast cancer. |
|
|
|
160-162 |
10.2122/gbc.2012.0240 |
|
Everolimus added to aromatase inhibitors for improving hormone-receptor-positive breast cancer outcomes. |
|
|
|
163-165 |
10.2122/gbc.2012.0241 |
|
Predictive molecular tools to personalized gastric cancer targeted therapy. |
|
|
|
166-179 |
10.2122/gbc.2012.0225 |
|
The emerging role of miRNAs in translational cancer medicine. |
|
|
|
180-195 |
10.2122/gbc.2012.0227 |
